Novo aims appease investors direct consumer plans blockbuster ambitions

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 12:07 UTC

With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a bright future for Novo.”